Case #a | Subtypea | PrPSc (SpC)b | SD50/gc |
---|
Control | MM1 | ND | >  5 × 109 |
3 | MV1 + 2C | 280 ± 103 | 5 × 109 |
4 | MV1 + 2C | 48 ± 9 | 9 × 107 |
9 CC | MV2K + 2C | 56 ± 12 | 8.9 × 1010 |
9 CbC | MV2K + 2C | 126 ± 15 | 2.8 × 1010 |
12 | MV2K + 2C | 90 ± 4 | 1.6 × 109 |
19 (iCJD) | MV2K | 133 ± 19 | 3.5 × 1011 |
10 | MV2K | 175 ± 19 | 1.2 × 1011 |
20 (iCJD) | MV2K | 171 + 44 | 1.6 × 1011 |
7 | MV2K | 581 ± 89 | 2.8 × 1011 |
18 (iCJD) | MV2K | 65 ± 7 | 2.8 × 1011 |
11 | MV2C | 290 ± 9 | 3.4 × 1010 |
- aNeuropathological subtype of cases originally described in [28]. All cases are sCJD except where noted as iCJD. CC cerebral cortex, CbC cerebellar cortex
- bSpC spectral counts. Total number of PrPSc peptides as determined by mass spectrometry of phosphotungstic acid precipitated CJD brain material For mean + standard deviation in previous sentence, please underline the + sign. are adapted from [28]
- cSD50/g = prion seeding doses (SD) yielding 50% positive wells in replicate RT-QuIC reactions per 1 g of MV brain homogenate [45]. Values were calculated from 3 independent end-point titration experiments